PRF Technologies Ltd.
PRFX evidence brief
What we can confirm
- Market Cap:
- $3.0M
What it means
What to watch
Prepared research question
What matters most for PRFX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRFX
PRF Technologies Ltd. (PRFX) is an early-stage biopharmaceutical company developing extended-release drug products, including its lead candidate OcuRing™-K, and has recently diversified into solar energy through its DeepSolar business, but has not yet commercialized any product or generated significant revenue.
Key risk: No revenue and ongoing losses
Market Cap
$3.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials for PRF Technologies Ltd..
PRF Technologies Ltd. (PRFX) is an early-stage biopharmaceutical company developing extended-release drug products, including its lead candidate OcuRing™-K, and has recently diversified into solar energy through its DeepSolar business, but has not yet commercialized any product or generated significant revenue.
- Lead product candidate is OcuRing™-K, an extended-release drug delivery system [sec · filed 2026-03-26].
- Cash and cash equivalents were $3.1M as of 2025-12-31 [sec].
- Net losses were $4.8M for the year ended December 31, 2025 [sec · filed 2026-03-26].
- Accumulated deficit was approximately $61.3M as of December 31, 2025 [sec · filed 2026-03-26].
- Company has not yet commercialized any drug candidates or its drug delivery system [sec · filed 2026-03-26].
What works
- The company has a proprietary extended-release drug-delivery system and is pursuing the 505(b)(2) regulatory pathway, which may offer a faster route to market [sec · filed 2025-04-07].
- PRF Technologies has identified a specific product candidate, OcuRing™-K, and has conducted clinical trials, indicating progress in development [sec · filed 2026-03-26].
- The company has recently acquired the DeepSolar business, diversifying its revenue potential beyond pharmaceuticals [sec · filed 2026-03-26].
What to weigh
- The company has never generated significant revenues and has incurred net losses of $4.8M in 2025, with an accumulated deficit of $61.3M as of December 31, 2025 [sec · filed 2026-03-26].
- PRF Technologies has identified a material weakness in its internal control over financial reporting, which could impair its ability to produce accurate financial statements [sec · filed 2026-03-26].
- The company faces significant uncertainty in obtaining regulatory approval and commercializing its product candidates, and may need substantial additional capital that may not be available on acceptable terms [sec · filed 2026-03-26].
- Manufacturing issues with its former CMO and product stability problems have caused delays in clinical trial batches [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
Company has not yet commercialized any drug candidates.
“have not yet commercialized our drug candidates, including OcuRing™-K, or our drug delivery system”
SEC filings · March 26, 2026
Net loss for 2025 was $4.8 million.
“We recorded net losses of $4.8 million, $14.6 million, and $9.3 million for the years ended December 31, 2025, 2024 and 2023”
SEC filings · March 26, 2026
Accumulated deficit as of December 31, 2025 was $61.3 million.
“As of December 31, 2025, we had an accumulated deficit of approximately $61.3 million.”
SEC filings · March 26, 2026
Material weakness in internal control over financial reporting.
“We have identified a material weakness in our internal control over financial reporting.”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Company has never generated significant revenue and incurred $4.8M net loss in 2025 [sec · filed 2026-03-26].
- Need for additional capital — Substantial additional funding required; may not be available on acceptable terms [sec · filed 2026-03-26].
- Regulatory and commercialization risk — Uncertainty in obtaining approval and commercializing OcuRing™-K [sec · filed 2026-03-26].
- Internal control weakness — Material weakness in financial reporting internal controls identified [sec · filed 2026-03-26].
What to watch
- Ability to raise additional capital and terms of financing [sec · filed 2026-03-26].
- Progress and outcomes of clinical trials for OcuRing™-K [sec · filed 2026-03-26].
- Remediation of material weakness in internal controls over financial reporting [sec · filed 2026-03-26].
- Commercialization progress of the DeepSolar business [sec · filed 2026-03-26].
Sources: SEC filings · Generated September 28, 2026 · How we verify sources →
Run PRF Technologies Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PRF Technologies Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 6.9%
- Days to cover
- 1.9
- Shares short
- 58,396
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRFX short interestFrequently asked questions
What is the AI investment thesis for PRF Technologies Ltd.?
PRF Technologies Ltd. (PRFX) is an early-stage biopharmaceutical company developing extended-release drug products, including its lead candidate OcuRing™-K, and has recently diversified into solar energy through its DeepSolar business, but has not yet commercialized any product or generated significant revenue.
Who is the CEO of PRF Technologies Ltd.?
Mr. Efraim Cohen-Arazi is the chief executive officer of PRF Technologies Ltd. (PRFX).
Where is PRF Technologies Ltd. headquartered?
PRF Technologies Ltd. (PRFX) is headquartered in Tel Aviv, Israel.
What therapeutic areas does PRF Technologies Ltd. focus on?
PRF Technologies Ltd. develops therapies across Oncology, Neurology, Immunology, Cardiovascular, Pain, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.